1. Jones PA, Issa JPJ, Baylin S (2016) Targeting the cancer epigenome for therapy. Nat Rev Genet 17:630–641
2. Nakagawa M, Oda Y, Eguchi T, Aishima S-I, Yao T, Hosoi F, Basaki Y, Ono M, Kuwano M, Tanaka M, Tsuneyoshi M (2007) Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 18:769–774
3. Eckschlager T, Plch J, Stiborova M, Hrabeta J (2017) Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 18:1–25
4. Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26:5541–5552
5. Uehara N, Yoshizawa K, Tsubura A (2012) Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells. Oncol Rep 28:105–110